Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q2 FY23 Earnings Presentation
20 slides from Ngl Fine-chem's earnings presentation, Nov 16, 2022
Slide 1: Cover letter to stock exchanges
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com November 16, 2022 To, Listing Department, Listing Department, The BSE Lim
Slide 2: NGL Fine-Chem Limited Investor Presentation Q2FY23
NGL Fine-Chem Limited INVESTOR PRESENTATION Q2FY23
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 10 Q2FY23 Over view, Highlights Key Strengths and Strategy Pg. No. 16 Historical Financial Performance
Slide 5: Q2FY23 Highlights
01 Q2FY23 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T O P E R AT I O N A L M E T R I C S
Slide 6: Management Commentary
MANAGEMENT COMMENTARY I am pleased to be repor ting to you on However, I am pleased to report that we have our per formance in Q2FY23. While the tackled the situation well and are now witnessing promising early signs of demand reviving back. overall operating environment continued On the product dev
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS (₹ IN CRORES) Q2FY22 Q1FY23 Q2FY23 PARTICULARS (₹ IN CRORES) Q2FY22 Q1FY23 Q2FY23 ANIMAL API 84% 88% 82% TOP 3 PRODUCTS 37% 34% 27% HUMAN API 7% 4% 8% TOP 5 PRODUCTS 54% 51% 41% INTERMEDIATES 7% 3% 6% FORMULATIONS 2% 5% 4% T
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q2FY22 Q1FY23 Q2FY23 Q-o-Q Y-o-Y H1FY22 H1FY23 Y-o-Y REVENUE FROM OPERATIONS 78.37 64.61 67.72 4.81% (13.59%) 154.23 132.33 (14.20%) OTHER INCOME 4.39 3.14 0.47 (85.03%) (89.29%) 8.94 3.61 (59.62%) TOTAL REVENUE 82.76 67.75 68.19 0.65% (1
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY22 H1FY23 SHAREHOLDERS FUND 203.22 206.85 NON CURRENT LIABILITIES 8.06 6.31 LONG TERM BORROWINGS 3.44 2.34 CURRENT LIABILITIES 65.65 60.92 SHORT TERM BORROWINGS 23.43 24.39 TOTAL EQUITY AND LIABILITIES 276.93 274.07 NON CURRENT ASSETS 103.44 113.80
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY22 H1FY23 CASH FLOW FROM OPERATING ACTIVITIES 13.83 26.33 CASH FLOW FROM INVESTING ACTIVITIES (14.21) (16.61) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW (1.46) 8.64 CASH AT THE BEGINNING OF YEAR 2.10 0.64 CASH AT THE END
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 A D VA N TA G E O U S LY P L A C E D I N A G R O W I N G OPPORTUNITY 15 S T R AT E G Y
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 24 APIs (22 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs, 2 Huma
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 34% CAGR CONCENTRATION (OF SALES FY22) backward integrated facilities leading to cost competitiveness FY22 258 CUSTOMER PRODUCT F
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Tarapur & Navi Mumbai, MANUFACTURING REACTORS REACTORS FACILITIES Maharashtra, designed to meet the requirements of regulatory agencies and are
Slide 15: Advantageously Placed in a Growing Opportunity
Advantageously Placed in a Growing Opportunity MARKET SIZE 2020 MARKET SIZE 2027 SEGMENT TRENDS GROWTH DRIVERS • Pharma segment to • Rising prevalence of grow at higher rate – zoonotic diseases, $139 Billion $192 Billion 5.4% CAGR animal population & pet ownership • Production animal ANIMAL HEALTH (
Slide 16: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION OUTSOURCE PRODUCTION DE-BOTTLENECKING • Completed ₹ 26 Cr expansion in • Target to outsource production • Continuous debottlenecking & ONGOING INITIATIVES subsidiary Macrotech to 15% by FY24 process improvements TO INCREASE • Additional capacities
Slide 17: Historical Financial Performance
03 Historical Financial Performance 17 ROBUST FINANCIAL PERFORMANCE 18 IMPROVING EFFICIENCIES
Slide 18: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT 27% 28% 35% (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) CAGR CAGR CAGR FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 FY19 153 FY19 32 FY19 20 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROSS
Slide 19: Improving Efficiencies
Improving Efficiencies ROCE Debt/Equity Fixed asset turnover (VALUES IN %) (VALUES IN X) (VALUES IN X) 60% 4 53% 0.30 3.4 3.4 0.25 3.5 50% 0.23 0.25 3 40% 2.5 34% 2.3 0.20 2.5 27% 0.13 30% 2 0.15 1.5 20% 0.10 12% 0.07 1 10% 0.05 0.5 0% 0 0.00 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY
Slide 20: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M